IL290454B2 - The compound dgd1202 for use in treating kras-associated cancers - Google Patents
The compound dgd1202 for use in treating kras-associated cancersInfo
- Publication number
- IL290454B2 IL290454B2 IL290454A IL29045422A IL290454B2 IL 290454 B2 IL290454 B2 IL 290454B2 IL 290454 A IL290454 A IL 290454A IL 29045422 A IL29045422 A IL 29045422A IL 290454 B2 IL290454 B2 IL 290454B2
- Authority
- IL
- Israel
- Prior art keywords
- compound
- salt
- cancer
- kras
- egfr
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962890119P | 2019-08-22 | 2019-08-22 | |
| PCT/US2020/047090 WO2021034992A1 (en) | 2019-08-22 | 2020-08-20 | Method of treating kras-associated cancers |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL290454A IL290454A (en) | 2022-04-01 |
| IL290454B1 IL290454B1 (en) | 2025-08-01 |
| IL290454B2 true IL290454B2 (en) | 2025-12-01 |
Family
ID=74660044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL290454A IL290454B2 (en) | 2019-08-22 | 2020-08-20 | The compound dgd1202 for use in treating kras-associated cancers |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220273643A1 (https=) |
| EP (1) | EP4017489B1 (https=) |
| JP (1) | JP7602272B2 (https=) |
| KR (1) | KR20220050143A (https=) |
| CN (2) | CN119454706A (https=) |
| AU (1) | AU2020334069B2 (https=) |
| BR (1) | BR112022003165A2 (https=) |
| CA (1) | CA3150759A1 (https=) |
| IL (1) | IL290454B2 (https=) |
| MX (1) | MX2022002108A (https=) |
| WO (1) | WO2021034992A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019217307A1 (en) | 2018-05-07 | 2019-11-14 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| EP3849537B1 (en) | 2018-09-10 | 2024-10-23 | Mirati Therapeutics, Inc. | Combination therapies |
| EA202190749A1 (ru) | 2018-09-10 | 2021-07-09 | Мирати Терапьютикс, Инк. | Способы комбинированной терапии |
| EP3849535A4 (en) | 2018-09-10 | 2022-06-29 | Mirati Therapeutics, Inc. | Combination therapies |
| JP2022500385A (ja) | 2018-09-10 | 2022-01-04 | ミラティ セラピューティクス， インコーポレイテッド | 組み合わせ療法 |
| MX2021002804A (es) | 2018-12-05 | 2021-07-15 | Mirati Therapeutics Inc | Terapias de combinacion. |
| EP3908283A4 (en) | 2019-01-10 | 2022-10-12 | Mirati Therapeutics, Inc. | KRAS G12C INHIBITORS |
| MX2022002465A (es) | 2019-08-29 | 2022-05-19 | Mirati Therapeutics Inc | Inhibidores de kras g12d. |
| WO2021061749A1 (en) | 2019-09-24 | 2021-04-01 | Mirati Therapeutics, Inc. | Combination therapies |
| PH12022551513A1 (en) | 2019-12-20 | 2023-04-24 | Mirati Therapeutics Inc | Sos1 inhibitors |
| EP4210833A4 (en) | 2020-09-11 | 2024-09-11 | Mirati Therapeutics, Inc. | CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR |
| JP2023553492A (ja) | 2020-12-15 | 2023-12-21 | ミラティ セラピューティクス， インコーポレイテッド | アザキナゾリン汎ＫＲａｓ阻害剤 |
| EP4262803A4 (en) | 2020-12-16 | 2025-03-12 | Mirati Therapeutics, Inc. | Tetrahydropyridopyrimidine pan-kras inhibitors |
| CA3214172A1 (en) * | 2021-04-02 | 2022-10-06 | Mukesh K. Nyati | Combination therapy for cancer treatment |
| WO2023003417A1 (ko) * | 2021-07-22 | 2023-01-26 | 국립암센터 | Kras 돌연변이 특이적 저해제 및 이를 포함하는 암 예방 또는 치료용 조성물 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
| CA2612183C (en) * | 2005-06-28 | 2015-08-11 | Genentech, Inc. | Egfr and kras mutations |
| WO2010114922A1 (en) * | 2009-03-31 | 2010-10-07 | Agios Pharmaceuticals, Inc. | Methods of treating cancer having an aberrant egfr or kras genotype |
| WO2012064642A1 (en) * | 2010-11-08 | 2012-05-18 | Glaxosmithkline Llc | Fatty acid synthase inhibitors |
| US20140256767A1 (en) | 2011-10-31 | 2014-09-11 | The Broad Institute, Inc. | Direct inhibitors of keap1-nrf2 interaction as antioxidant inflammation modulators |
| WO2014176475A2 (en) | 2013-04-26 | 2014-10-30 | The Regents Of The University Of Michigan | Egfr inhibitors and uses thereof |
| EP3755323A4 (en) * | 2018-02-23 | 2021-11-24 | The Regents Of The University Of Michigan | EGFR DIMER DISRUPTORS AND THEIR USES |
-
2020
- 2020-08-20 MX MX2022002108A patent/MX2022002108A/es unknown
- 2020-08-20 CA CA3150759A patent/CA3150759A1/en active Pending
- 2020-08-20 JP JP2022511096A patent/JP7602272B2/ja active Active
- 2020-08-20 AU AU2020334069A patent/AU2020334069B2/en active Active
- 2020-08-20 EP EP20854314.0A patent/EP4017489B1/en active Active
- 2020-08-20 IL IL290454A patent/IL290454B2/en unknown
- 2020-08-20 WO PCT/US2020/047090 patent/WO2021034992A1/en not_active Ceased
- 2020-08-20 BR BR112022003165A patent/BR112022003165A2/pt unknown
- 2020-08-20 US US17/634,265 patent/US20220273643A1/en not_active Abandoned
- 2020-08-20 CN CN202411400491.9A patent/CN119454706A/zh active Pending
- 2020-08-20 CN CN202080059528.XA patent/CN114286676A/zh active Pending
- 2020-08-20 KR KR1020227007201A patent/KR20220050143A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021034992A1 (en) | 2021-02-25 |
| AU2020334069A1 (en) | 2022-03-24 |
| CN114286676A (zh) | 2022-04-05 |
| EP4017489B1 (en) | 2025-05-07 |
| JP2022545005A (ja) | 2022-10-24 |
| BR112022003165A2 (pt) | 2022-05-17 |
| AU2020334069B2 (en) | 2026-02-19 |
| IL290454A (en) | 2022-04-01 |
| JP7602272B2 (ja) | 2024-12-18 |
| CN119454706A (zh) | 2025-02-18 |
| KR20220050143A (ko) | 2022-04-22 |
| CA3150759A1 (en) | 2021-02-25 |
| IL290454B1 (en) | 2025-08-01 |
| EP4017489A4 (en) | 2023-08-23 |
| EP4017489C0 (en) | 2025-05-07 |
| US20220273643A1 (en) | 2022-09-01 |
| MX2022002108A (es) | 2022-03-17 |
| EP4017489A1 (en) | 2022-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL290454B2 (en) | The compound dgd1202 for use in treating kras-associated cancers | |
| US20210100813A1 (en) | Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors | |
| JP5931982B2 (ja) | （ａ）ホスホイノシタイド３−キナーゼ阻害剤および（ｂ）Ｒａｓ／Ｒａｆ／Ｍｅｋ経路のモジュレーターの配合物 | |
| US20220008426A1 (en) | Therapeutic combinations comprising a c-raf inhibitor | |
| EP2785349B1 (en) | Combination treatment of cancer | |
| WO2022106711A1 (en) | Combination comprising abemaciclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid | |
| KR20220003560A (ko) | 유잉 육종의 치료를 위한 퀴놀린 화합물 또는 그의 약제학적으로 허용 가능한 염 | |
| WO2024137778A1 (en) | Cancer treatments using mta-cooperative prmt5 inhibitors | |
| WO2010063698A1 (en) | Treatment of oncological diseases | |
| EP2754441A2 (en) | Composition for preventing and treating non-small cell lung cancer, containing pyrazino-triazine derivatives | |
| UA123403C2 (uk) | Спосіб лікування хворих на рак з тяжкою нирковою недостатністю | |
| WO2020029918A1 (zh) | 用于治疗结外nk/t细胞淋巴瘤的喹啉衍生物 | |
| Shi et al. | CTNI-09. Trident phase 3 trial (EF-32): first-line tumor treating fields (TTFields; 200 KHZ) concomitant with chemo-radiation, followed by maintenance ttfields/temozolomide in newly-diagnosed glioblastoma | |
| HK40127963A (zh) | 治疗egfr突变阳性非小细胞肺癌伴脑转移的表皮生长因子受体酪氨酸激酶抑制剂 | |
| MX2023005908A (es) | Metodos para usar 4-amino-n-[4-(metoximetil)fenil]-7-(1- metilciclopropil)-6-(3-morfolinoprop-1-in-1-il)-7h-pirrolo[2,3- d]pirimidina-5-carboxamida para el tratamiento de tumores. | |
| HK1227400B (en) | Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors | |
| HK1227400A1 (en) | Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors | |
| HK40027220A (en) | Coumarin derivative for therapy or prophylaxis of a disorder of cell proliferation | |
| HK40004186A (en) | Therapeutic combinations comprising a raf inhibitor and a erk inhibitor | |
| HK40004186B (en) | Therapeutic combinations comprising a raf inhibitor and a erk inhibitor | |
| HK1202253B (en) | Combination treatment of cancer | |
| HK1161114B (en) | Use of alkanoyl l-carnitine in combination with chemotherapeutic agents for the treatment of neoplasms | |
| NZ625611B2 (en) | Combination treatment of cancer |